Rigel Pharmaceuticals Inc (NAS:RIGL)
$ 16.5 -0.76 (-4.4%) Market Cap: 304.04 Mil Enterprise Value: 303.15 Mil PE Ratio: 75.04 PB Ratio: 0 GF Score: 77/100

Rigel Pharmaceuticals Inc to Discuss FORWARD Study Results Transcript

Jun 08, 2022 / 12:00PM GMT
Release Date Price: $7.01 (-60.20%)
Operator

Greetings, and welcome to the Rigel Pharmaceuticals conference call to discuss FORWARD study results. (Operator Instructions)

As a reminder, this conference is being recorded. I would now like to turn the call over to Dolly Vance, Executive Vice President, Corporate Affairs and General Counsel. Thank you. You may begin.

Dolly A. Vance
Rigel Pharmaceuticals, Inc. - Executive VP of Corporate Affairs, General Counsel & Corporate Secretary

Welcome, and thank you for joining us today to discuss topline results from the FORWARD pivotal Phase III clinical trial of fostamatinib in patients with warm autoimmune hemolytic anemia, who have failed at least one prior treatment. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties and may cause actual results to differ from those forecasted.

A description of these risks can be found in our most recent annual report on Form 10-K

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot